Quantcast

Latest Scilex Pharmaceuticals Inc. Stories

2014-09-10 16:26:06

MALVERN, Pa., Sept. 10, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that it will participate in the upcoming Aegis Capital 2014 Healthcare & Technology Conference to be held at The Encore At Wynn in Las Vegas. The management of the Company will present at 8:30 a.m. on September 11, 2014. About SCILEX Pharmaceuticals SCILEX Pharmaceuticals, Inc., located...

2014-08-19 08:30:53

MALVERN, Pa., Aug. 19, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products for the treatment of pain, announced that it had formed a Scientific Advisory Board composed of four members: Dr. Jeff Gudin, Dr. Charles Argoff, Dr. Srinivas Nalamachu and Mr. Kip Vought. SCILEX Chief Executive Officer Anthony Mack said the expertise of this board would greatly assist in the development and...

2014-08-11 08:30:05

All studies on track for completion and final study reports by November 2014 MALVERN, Pa., Aug. 11, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has completed patient enrollment for the dermal safety studies and the pivotal pharmacokinetic study related to its investigational product Ztlido (lidocaine patch 1.8%), a...

2014-07-14 12:27:21

The Company expects the studies, along with the PK study, to be completed in the 4th quarter of 2014 MALVERN, Pa., July 14, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has commenced dermal safety studies of its Ztlido (lidocaine patch 1.8%) product candidate, a next-generation branded lidocaine patch for the treatment of...

2014-05-19 08:29:19

Scilex has commenced with its pivotal bioequivalence study of Ztilido versus Lidoderm® in accordance with FDA recommendations to support approval of Ztilido submitted as a 505(b)(2) NDA MALVERN, Pa., May 19, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has initiated a pivotal pharmacokinetic (PK) study of its investigational...

2014-05-05 08:30:14

Mr. Sendrow Joins Pharmaceuticals Product Development and Regulatory Expert Eric Floyd, Ph.D. on the Board MALVERN, Pa., May 5, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of finance and accounting veteran Jerrold Sendrow to the Company's board of directors. Mr. Sendrow brings to SCILEX twenty-eight years of experience in finance and...

2014-03-24 08:29:56

Pivotal pharmacokinetic bridging clinical study anticipated to begin in May MALVERN, Pa., March 24, 2014 /PRNewswire/ -- Scilex Pharmaceuticals, Inc., a company engaged in the development and commercialization of products for the treatment of pain, today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration for its first product Ztilido(TM) (lidocaine patch 1.8%). The FDA Division of Anesthesia and Analgesia Products...

2014-03-21 08:25:35

Funds to be used for the clinical development of the Company's first product Ztilido(TM) (lidocaine patch 1.8%) MALVERN, Pa., March 21, 2014 /PRNewswire/ -- Scilex Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that it has entered into definitive agreements for a private placement of common stock and warrants. The gross proceeds of the placement are expected to be approximately...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.